Welcome to our dedicated page for ymtx news (Ticker: ymtx), a resource for investors and traders seeking the latest updates and insights on ymtx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ymtx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ymtx's position in the market.
Yumanity Therapeutics (Nasdaq: YMTX) announced a stock option grant to a new employee for 30,000 shares at an exercise price of $10.88. The option vests over four years, with 25% vesting after one year and the remainder monthly thereafter. This option aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for the new hire. Yumanity is focused on developing therapies for neurodegenerative diseases, with its leading candidate YTX-7739 in Phase 1 trials for Parkinson's disease. The company is committed to innovating treatments for various neurodegenerative conditions.
Yumanity Therapeutics (NASDAQ: YMTX) announced that CEO Richard Peters, M.D., Ph.D., will present at the H.C. Wainwright 23rd Global Investment Conference. The presentation will be accessible on-demand through the conference portal and the company’s website starting September 13 at 7 a.m. EDT.
Yumanity focuses on developing therapies for neurodegenerative diseases, with its leading candidate, YTX-7739, currently in Phase 1 clinical trials for Parkinson’s disease. The company also has programs targeting conditions like Alzheimer’s and ALS.
Yumanity Therapeutics (NASDAQ: YMTX) has appointed Michael D. Wyzga as Senior Vice President and Chief Financial Officer. Mr. Wyzga brings over a decade of healthcare finance experience, most recently from Needham & Company. His appointment is expected to enhance the company's strategic and operational capabilities as it focuses on developing therapies for neurodegenerative diseases, particularly the lead program YTX-7739 for Parkinson’s. Additionally, inducement equity awards were granted to Mr. Wyzga and two new employees, highlighting the company's commitment to strengthening its leadership.
Yumanity Therapeutics (NASDAQ: YMTX) reported significant progress in its clinical program YTX-7739 for Parkinson’s disease during Q2 2021. The drug showed well-tolerated target engagement in healthy subjects. The company appointed Ajay Verma as EVP of R&D and Devin Smith as General Counsel. Financially, cash reserves decreased to $55.6 million from $85.3 million due to R&D expenses of $7.3 million and administrative costs of $4.7 million. The net loss widened to $10.5 million, or $1.03 per share, compared to $7.0 million in Q2 2020. Upcoming milestones include the Phase 1b trial results expected in Fall 2021.
Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focusing on neurodegenerative diseases, announced participation in a fireside chat at the BTIG Virtual Biotechnology Conference on August 10, 2021, at 1:00 p.m. ET. This event is exclusive to BTIG clients. Yumanity is advancing innovative therapies, with its lead candidate, YTX-7739, in Phase 1 for Parkinson’s disease. The company aims to overcome misfolded protein toxicity through its drug discovery platform, targeting conditions such as Lewy body dementia, ALS, FTLD, and Alzheimer’s.
Yumanity Therapeutics (NASDAQ: YMTX) has appointed Devin W. Smith as Senior Vice President and General Counsel, effective immediately. Mr. Smith brings extensive experience from his previous roles at Minerva Neurosciences and Stallergenes Greer. His expertise is expected to be crucial as Yumanity advances its three clinical programs and seeks to expand corporate partnerships. Smith will receive an option to purchase 58,400 shares, vesting over four years. The company focuses on developing therapies for neurodegenerative diseases, with its lead candidate, YTX-7739, currently in Phase 1 trials for Parkinson's disease.
BOSTON, May 27, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX) announces that Richard Peters, M.D., Ph.D., President and CEO, will present at two upcoming virtual investor conferences in June. The presentations are scheduled for:
- Jefferies Virtual Healthcare Conference on June 3 at 11:00 AM Eastern Time
- JMP Securities Life Sciences Conference on June 16 at 2:00 PM Eastern Time
BOSTON, May 17, 2021 - Yumanity Therapeutics (NASDAQ: YMTX) announced significant advancements at its R&D Day, focusing on three clinical programs: the ongoing YTX-7739 Phase 1b program for Parkinson’s disease, the initiation of YTX-9184 studies for dementia with Lewy bodies, and a glioblastoma study launching in early 2022. The company reported positive early results for YTX-7739, which targets a toxic pathway associated with neurodegeneration and has shown promise in reducing motor function deficits in animal models. Initial data for YTX-7739 is expected mid-2021.
Yumanity Therapeutics (NASDAQ: YMTX) reported first-quarter 2021 financial results, showing a net loss of $8.7 million, or $0.85 per share. The company is advancing its lead program, YTX-7739, which demonstrated target engagement and improved motor function in a mouse model of Parkinson’s disease. The Phase 1a trial in healthy volunteers showed favorable results, leading to the initiation of the Phase 1b trial. The cash position decreased to $62.9 million due to clinical expenses, but is expected to fund operations into Q3 2022. Upcoming milestones include preliminary Phase 1b results by mid-2021.
Yumanity Therapeutics (NASDAQ: YMTX) is set to present at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 5:25 p.m. EDT. Richard Peters, M.D., Ph.D., the Company's CEO, will lead the presentation. A live audio webcast will be available on the company's website, with an archived replay accessible afterward. Yumanity focuses on therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's.
